Click to listen to this article.
Camber marked a strong first half of 2025 with the launch of 24 new products, including a mix of generic drugs, specialty generics, and OTC medications. These launches reflect Camber’s continued investment in expanding patient access to high-quality, affordable treatments.
Since establishing its U.S. operations 18 years ago, Camber has grown into a leading generic pharmaceutical company with a diverse portfolio of over 250 products, including 20 specialty drugs and 16 OTC offerings. In 2025 alone, the company expects to file approximately 35 Abbreviated New Drug Applications (ANDAs) and secure approvals for 54 additional products.
2025 Launches to Date include:
- Bortezomib Injection
- Bupivacaine HCl Injection
- Chlorpromazine Injection
- Chlorzoxazone Tablets
- Dicyclomine Tablets
- Eltrombopag Oral Solution
- Eltrombopag Tablets
- Eslicarbazepine Acetate Tablets
- Lurasidone Tablets
- Mycophenolate Capsules
- Mycophenolate Tablets
- Nimodipine Oral Solution
- Olmesartan Medoxomil Tablets
- Phenylephrine HCl Injection
- Posaconazole Injection
- Quetiapine Fumarate Tablets
- Sirolimus Oral Solution
- Sodium Sulfate/Potassium Sulfate and Magnesium Sulfate Oral Solution
- Temozolomide Capsules
- Carbidopa/Levodopa Tablets
- Colchicine Capsules
- Prucalopride Tablets
- Daytime Cold / Flu High Blood Pressure
- Tussin Cough Formula Expectorant
Looking ahead, Camber’s regulatory and product launch teams anticipate an even more accelerated pace in the second half of the year, with a goal of launching 60 new products in 2025.
For more information about these launches or to learn more about Camber’s expanding pipeline, please contact your Camber representative.
